Links to the following videos are also available online underneath the article abstract.

Similar documents
ORIGINAL RESEARCH. 224 Journal of Renal Nutrition, Vol 20, No 4 (July), 2010: pp

Table 1 Baseline characteristics of 60 hemodialysis patients with atrial fibrillation and warfarin use

Variable Included. Excluded. Included. Excluded

Appendix F: Test-Curriculum Matching Analysis

Evaluation of Asthma Management in Middle EAst North Africa Adult population

Appendix F. The Test-Curriculum Matching Analysis Science TIMSS 2011 INTERNATIONAL RESULTS IN SCIENCE APPENDIX F 479

It is simply an acronym (short-form) of Gulf Cooperation Council. Members of the Gulf Cooperation Council are ;

Screening for depression in hemodialysis patients: Associations with diagnosis, treatment, and outcomes in the DOPPS

SUPPLEMENTARY DATA. Supplementary Figure S1. Cohort definition flow chart.

State Profile for FY 2018 for Dialysis Patients and Facilities - STATE SAMPLE

EPIDEMIOLOGY OF CANCER IN THE GULF REGION. Khoja, T. 1, Zahrani A. 2

A n aly tical m e t h o d s

Clinical Study Synopsis

MENTAL HEALTH CARE. OECD HCQI Expert meeting 17 th of May, Rie Fujisawa

The Test-Curriculum Matching Analysis: Science

Serum levels of galectin-1, galectin-3, and galectin-9 are associated with large artery atherosclerotic

Design and Analysis of a Cancer Prevention Trial: Plans and Results. Matthew Somerville 09 November 2009

David C. Mendelssohn MD, FRCPC DOPPS Update 2010

Enriched RWE study in the Nordics a case study

THE DIALYSIS OUTCOMES and Practice

Haemodiafiltration - the case against. Prof Peter G Kerr Professor/Director of Nephrology Monash Health

IN-CENTER HEMODIALYSIS (HD) CLINICAL PERFORMANCE MEASURES DATA COLLECTION FORM 2006

Designing a Smoke-Free Future

Brigitte Khoury, Ph.D. Director, Arab Regional Center for Research, Training and Policy Making in Mental Health Dept. of Psychiatry, American

A Summary of Childhood Cancer Statistics in Australia,

Field of Post-M.D. Training

The influence of societal individualism on a century of tobacco use: modelling the prevalence of smoking Appendices A and B

Supplementary information file

GLOBAL FMD SITUATION DURING 2001/2002

2011 Dialysis Facility Report

Injection Techniques Questionnaire (ITQ) WorldWide Results Needle Gauge

Cancer Incidence and Mortality in the Kingdom of Bahrain Statistics and Trends

2011 Dialysis Facility Report SAMPLE Dialysis Facility State: XX Network: 99 CCN: SAMPLE Dialysis Facility Report SAMPLE

Cancer in the Arabian Gulf Kingdom of Bahrain ( ) Fayek A Alhilli, PhD (Path)* Nagalla S Das, MD*

The study was cross-sectional, conducted during the academic year 2004/05.

Itchy skin a clinical problem for haemodialysis patients

The FIND-CKD Study Background Study design (Results)

Table 15.1 Summary information for kidney cancer in Ireland, Ireland RoI NI female male female male female male % of all new cancer cases

Does cannulation technique impact arteriovenous fistula and graft survival? Maria Teresa Parisotto CANNT 2017 Halifax October 20 th, 2017

Prof. Renata Cífková, MD, CSc.

A cohort study to find Incidence of Peripheral Arterial Disease in

Main developments in past 24 hours

A Global perspective on Heart Failure: What needs to change? Martin R Cowie London, United Kingdom

Secondary prevention and systems approaches: Lessons from EUROASPIRE and EUROACTION

ORBE Summary of Benefits

Multivariate relationships. Week 6 22 February, 2016 Prof. Andrew Eggers

6 th Dental-Facial Cosmetic International Conference 2014

The JUPITER trial: What does it tell us? Alice Y.Y. Cheng, MD, FRCPC January 24, 2009

STABILITY Stabilization of Atherosclerotic plaque By Initiation of darapladib TherapY. Harvey D White on behalf of The STABILITY Investigators

NobelProcera Implant Bar Overdenture EXPERIENCE THE NEW WORLD OF CAD/CAM DENTISTRY

Nutritional Cases with CKD HEMODIALYSIS

Supplementary Online Content

Status of the CKD and ESRD treatment: Growth, Care, Disparities

Chronic kidney disease (CKD) has received

Global EHS Resource Center

(n=6279). Continuous variables are reported as mean with 95% confidence interval and T1 T2 T3. Number of subjects

Supplementary Table S1: Proportion of missing values presents in the original dataset

Injection Techniques Questionnaire (ITQ) WorldWide Results Insulin Usage

GSK Medicine: Study Number: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives:

Original Articles INTRODUCTION

Pharmaceuticals Import Summary Report. selected countries in MENA region

HPV the silent killer, Prevention and diagnosis

2008 Dialysis Facility Report

Modelling diabetes Professor Alastair Gray Health Economics Research Centre University of Oxford

The Renal Physicians Association Quality Improvement Registry

NATIONAL QUALITY FORUM Renal EM Submitted Measures

Prohibition of importation, manufacturing and sale of Smokeless Tobacco products.

RETROSPECTIVE CLAIMS DATABASE STUDIES OF DIRECT ORAL ANTICOAGULANTS (DOACS) FOR STROKE PREVENTION IN NONVALVULAR ATRIAL FIBRILLATION

Terms and Conditions. VISA Global Customer Assistance Services

Ferrari R, Fox K, Bertrand M, Mourad J.J, Akkerhuis KM, Van Vark L, Boersma E.

Emily J. Hadgkiss, 1 George A. Jelinek, 1,2 Tracey J. Weiland, 1,3 Naresh G. Pereira, 4 Claudia H. Marck, 1 and Dania M.

Nephrology Unit- CHU Liège- Ulg- Belgium

Pharmaceutical, Medical and Health-related Government and Regulatory bodies around the world.

Protocol GTC : A Randomized, Open Label, Parallel Design Study of Sevelamer Hydrochloride (Renagel ) in Chronic Kidney Disease Patients.

John J.P. Kastelein MD PhD Professor of Medicine Dept. of Vascular Medicine Academic Medial Center / University of Amsterdam

Trial to Reduce. Aranesp* Therapy. Cardiovascular Events with

Targeted Deprescribing in Patients on Hemodialysis to Decrease Polypharmacy

Home Hemodialysis or Transplantation of the Treatment of Choice for Elderly?

Urogenital Malignancies Oct 15-17,2010 Constantine Algeria. President of Jordan Oncology Society Secretary General of AMAAC

Treated ESRD Incidence Rate for Selected Countries, New Patients/Million Pop. 250 USA (All) USRDS 1996

Do We Do Too Many Parathyroidectomies in Dialysis? Sagar Nigwekar MD, MMSc Massachusetts General Hospital

National Strategy. for Control and Prevention of Non - communicable Diseases in Kingdom of Bahrain

Autonomic nervous system, inflammation and preclinical carotid atherosclerosis in depressed subjects with coronary risk factors

Clinical Performance Measures for ESRD Patients. Lana Kacherova, QI Director, ESRD Network th Annual NANT Symposium February 12, 2009

Supplementary Online Content

WebEx Quick Reference

Cardiovascular Risk Reduction in Kidney Transplant Recipients

AC T I O N - O R I E N T E D H O P E - C E N T E R E D C A R E E R D E V E L O P M E N T

Models of preventive care in clinical practice to achieve 25 by 25

Biostatistics and Epidemiology Step 1 Sample Questions Set 1

Hemodiafiltration in Europe : Trends, Practices, Outcomes & Perspectives

Lesson #7: Quality Assessment and Performance Improvement

Brazil Editors: LEO Innovation Lab and The Happiness Research Institute Copenhagen, Denmark, October 2018

Ying Liu, 1 Wen-Chin Lee, 2 Ben-Chung Cheng, 2 Lung-Chih Li, 2 Chih-Hsiung Lee, 2 Wen-Xiu Chang, 1 and Jin-Bor Chen 2. 1.

Usefulness of the Japanese version of the 5-D itch scale for rating pruritus experienced by patients undergoing hemodialysis

Large observational study to UNderstand the Global impact of Severe Acute respiratory FailurE (LUNG-SAFE)

Ying-Ping Sun, Wen-Jun Yang, Su-Hua Li, Yuan-yuan Han, and Jian Liu

Applying clinical guidelines treating and managing CKD

Diagnosis: Allergies with reaction type:

S150 KEEP Analytical Methods. American Journal of Kidney Diseases, Vol 55, No 3, Suppl 2, 2010:pp S150-S153

Transcription:

Supplementary Materials: Links to the following videos are also available online underneath the article abstract. 1. Supplementary Video 1: Itching due to kidney failure A patient s experience (vimeo.com/49458473) 2. Supplementary Video 2: Gabapentin treatment for itching A patient s experience (vimeo.com/49455976) 1

Supplementary Table 1: Patient characteristics according to the extent to which patients were bothered by itchy skin. (Expanded Table 1 showing categories of lab measures and p values) To what extent were you bothered by itchy skin during the past 4 weeks? Not at all Somewhat Moderately Very much Extremely Total sample, N 2111 1840 1188 692 425 Total sample, % 34 29 19 11 7 Patient characteristics: Male Age, years Time on dialysis, years < 0.25 0.25 <1 1 <5 5 <10 10 BMI, kg/m2 Treatment time (min) Hemodiafiltration (HDF) B 60 59 60 60 59 62(15) 62(15) 63(15) 63(15) 64(15) 8 5 6 6 7 12 11 11 14 12 45 45 47 46 48 19 23 22 19 19 16 17 14 15 14 26(6) 25(6) 26(7) 26(6) 26(7) 237(34) 237(35) 235(31) 232(32) 232(28) AOR A [95% CI] 1.01 [0.91, 1.12] 1.06 [1.02, 1.10] 0.98 [0.83, 1.15] 1.01 [0.88, 1.15] 1.03 [0.92, 1.15] 0.97 [0.85, 1.09] 1.05 [, 1.11] 0.99 [0.97, ] Non HDF 82 85 84 85 84 HDF 4 15 L 3 4 5 3 5 1.04 [0.78, 1.37] HDF 15 20 L 5 3 4 4 3 1.01 [0.77, 1.32] HDF >20 L 11 8 8 9 8 0.92 2

Smoker C 19 21 22 24 21 Hepatitis B/C Labs: Hemoglobin, g/dl PTH, pg/ml White Blood Cell count 6 8 9 9 9 11.0(1.4) 11.0(1.4) 11.0(1.4) 11.0(1.4) 10.9(1.5) 355(416) 348(449) 346(496) 322(345) 349(430) <5400 29 30 28 27 27 5400 <6700 24 25 27 27 24 6700 <8400 28 25 25 27 22 8400 19 20 20 20 26 Albumin (g/dl) < 3.5 23 23 26 28 34 3.5 <4.0 42 44 43 44 40 4.0 34 33 30 28 26 Albumin (g/dl) continuous Ferritin (ng/ml) 3.8(0.5) 3.7(0.5) 3.7(0.5) 3.7(0.5) 3.7(0.5) < 100 17 24 18 18 18 100 <400 32 30 33 33 32 400 <800 29 28 30 30 31 800 23 18 19 19 19 Calcium (mg/dl) < 8.4 21 22 24 23 21 [0.72, 1.17] 1.15 [0.97, 1.35] 1.26 [1.06, 1.50] 0.99 [0.95, 1.03] 0.99 [0.98, 1.01] 1.07 [0.98, 1.18] 0.93 [0.85, 1.03] 1.08 [0.98, 1.19] 1.14 [1.04, 1.25] 0.87 [0.80, 0.95] 0.86 [0.75, 0.98] 0.92 [0.79, 1.06] 1.03 [0.92, 1.15] 1.01 [0.89, 1.14] 1.02 [0.91, 1.15] 3

8.4 <9.5 57 56 55 53 58 9.5 <10.2 18 17 16 19 19 10.2 4 5 5 4 3 Phosphorus (mg/dl) < 3.5 11 11 13 11 13 3.5 <5.5 56 51 52 51 50 5.5 <6.7 20 23 21 22 20 6.7 13 15 14 15 16 Calcium x Phosphorus product (mg 2 /dl 2 ) Single Pool Kt/V 43[36,52] 45[36,55] 44[35,52] 44[36,53] 44[36,54] < 1.2 14 18 17 18 19 1.2 <1.5 33 34 34 35 34 1.5 53 49 49 47 47 CRP (mg/l) D < 1 1 <3 3 <5 5 <10 10 <15 15 CRP (mg/l) D continuous 1.02 [0.89, 1.15] 0.98 [0.80, 1.21] [0.88, 1.14] 1.01 [0.91, 1.13] 1.07 [0.95, 1.21] 1.02 [0.98, 1.06] 1.02 [0.92, 1.13] 0.95 [0.86, 1.04] 24 24 23 25 17 25 28 22 19 20 0.77 (0.65, 0.91) 13 13 9 10 8 0.68 (0.52, 0.90) 17 18 22 21 18 1.18 (0.94, 1.47) 7 5 8 7 10 1.39 (1.06, 1.83) 14 13 16 18 26 1.31 (1.05, 1.64) 3.0 [1.0,8.0] 2.7 [1.0,7.0] 4.0 [1.0,9.7] 4.0 [1.0,10.5] 5.3 [1.7,15.8] [, 1.01] 4

Footnote: Data shown as mean (standard deviation), median [interquartile range], or column percent. Non response rate was 27% overall, varying from 9% in Turkey to 46% in Canada. A. Each variable tested in separate logistic regression model with moderately to severely being bothered by itchy skin as the outcome accounting for facility clustering and adjusting for age, sex, vintage, 13 summary comorbidities (coronary artery disease, cancer, other cardiovascular disease, cerebrovascular disease, congestive heart failure, diabetes mellitus, gastrointestinal bleeding, hypertension, lung disease, neurologic disorder, psychological disorder, peripheral vascular disease, recurrent cellulitis), and country. Adjusted odds ratio (95% confidence interval) shown for age per 10 years, BMI per 5 kg/m 2, treatment time per 10 minutes, calcium phosphorus product per 10 mg 2 /dl 2. B. Hemodiafiltration (HDF) measure excludes US and Canada due to lack of use; n=4774 C. Smoker defined as someone indicating being a current smoker or stopped smoking within past year D. CRP is restricted to facilities that reported measurement in at least 50% of patients (excludes US), n=2066 5

Supplementary Table 2 What time of the day is the itch most bothersome? When is the itch most bothersome in relation to your dialysis treatments? % N % N 1: Morning 5% 43 1: Soon before the dialysis session 2% 20 2: Afternoon 3% 31 2: During the dialysis session 15% 138 3: Evening 15% 145 3: Soon after the dialysis 9% 85 4: At night 30% 282 4: On non dialysis days 14% 128 5: No specific time, 5: No specific time, 48% 454 or most all times or most all times 61% 576 All 100% 955 All 100% 947 Time of day and timing in relation to dialysis treatment that itch is most bothersome in patients who answered Yes to question Are you bothered at all by itchy skin? 6

Supplementary Table 3: Health care providers that patients spoke with about their itchy skin. Nephrologist Nurses or other staff Skin doctor Primary care doctor None Total responders: Nearly Always or Always bothered by itchy skin Overall bothered by itchy skin All Bel Can GCC Ger Ita Jpn Rus Spa Swe Tur UK US 42% 46% 59% 59% 70% 46% 84% 34% 62% 55% 71% 26% 46% 26% 32% 37% 26% 51% 23% 33% 35% 44% 29% 36% 41% 31% 32% 39% 18% 24% 26% 16% 31% 32% 38% 27% 11% 15% 18% 31% 16% 17% 16% 19% 4% 27% 2% 33% 24% 9% 29% 15% 9% 21% 44% 37% 25% 17% 11% 18% 12% 14% 8% 13% 12% 19% 21% 19% 19% 33% 2522 999 27 49 98 57 37 338 73 73 34 42 57 114 Footnote: Question wording: What health care providers have you spoken with about your itchy skin (choose all that apply)? ; restricted to patients who answered Yes to question Are you bothered at all by itchy skin? (presented in Overall column) and also selected 5 or 6 ( Nearly Always or Always bothered ) on 0 6 scale in response to During the past week, how often have you been bothered by: your itching?. ANZ = Australia and New Zealand, Bel = Belgium, Can = Canada, Chi = China, GCC = the six Gulf Cooperation Council countries (Bahrain, Qatar, Kuwait, Oman, Saudi Arabia, and United Arab Emirates), Ger = Germany, Ita = Italy, Jpn = Japan, Rus = Russia, Spa = Spain, Swe = Sweden, Tur = Turkey, UK = the United Kingdom, US = the United States of America. 7

Supplementary Table 4: Health care providers that prescribed treatments/medications for patients with itchy skin. Overall bothered by itchy skin Nearly Always or Always bothered by itchy skin All Bel Can GCC Ger Ita Jpn Rus Spa Swe Tur UK US Nephrologist 52% 52% 55% 59% 79% 49% 69% 46% 60% 68% 89% 33% 29% 27% Nurses or other staff 23% 23% 18% 24% 11% 16% 0% 30% 13% 25% 18% 33% 7% 36% Skin doctor 24% 26% 32% 26% 33% 33% 31% 28% 17% 17% 18% 33% 17% 21% Primary care doctor 19% 18% 14% 26% 0% 21% 29% 8% 25% 13% 14% 20% 59% 46% Total responders: 1927 832 22 34 91 43 35 314 53 53 28 40 41 78 Footnote: Question wording: Which health care providers have prescribed treatments/medications for your itchy skin (choose all that apply)? ; restricted to patients who answered Yes to question Are you bothered at all by itchy skin? (presented in Overall column) and also selected 5 or 6 ( Nearly Always or Always bothered ) on 0 6 scale in response to During the past week, how often have you been bothered by: your itching?. ANZ = Australia and New Zealand, Bel = Belgium, Can = Canada, Chi = China, GCC = the six Gulf Cooperation Council countries (Bahrain, Qatar, Kuwait, Oman, Saudi Arabia, and United Arab Emirates), Ger = Germany, Ita = Italy, Jpn = Japan, Rus = Russia, Spa = Spain, Swe = Sweden, Tur = Turkey, UK = the United Kingdom, US = the United States of America. 8

Supplementary Table 5: Medical Director s ranking of therapeutic options for patients with severe pruritus. % of Medical Directors Increasing dialysis dose (in patients with low Kt/V) Phosphorus control (in patients with high serum phosphorus) Lowering PTH levels (in patients with high PTH) Use of prescription medications for pruritus Increasing prescribed treatment time (in patients with short treatment time) Rank of Importance 1 (most) 2 3 4 5 (least) 15% 25% 29% 24% 6% 60% 16% 15% 8% 1% 2% 26% 21% 28% 23% 13% 15% 13% 14% 45% 11% 18% 21% 26% 24% Footnote: Question wording: Please rank the following therapeutic options for patients with severe pruritus in order of importance (from 1 to 5, with 1 being most important) ; restricted to complete responses, N=241 9

Supplementary Table 6: Treatments/medications patient was taking to relieve itchy skin. Overall Nearly Always or Always bothered by itchy skin bothered by itchy All Bel Can GCC Ger Ita Jpn Rus Spa Swe Tur UK US skin Non Rx topical 29% 30% 21% 51% 42% 51% 24% 17% 35% 29% 36% 12% 25% 45% Rx topical 38% 44% 36% 31% 33% 25% 38% 72% 6% 26% 42% 36% 46% 23% Non Rx oral 7% 7% 4% 4% 14% 5% 11% 1% 17% 4% 3% 12% 4% 14% Rx oral 19% 22% 29% 24% 24% 12% 38% 22% 7% 30% 45% 31% 15% 17% Ultraviolet (UV) light 1% 1% 0% 0% 3% 0% 0% 1% 1% 1% 0% 0% 0% 0% treatment None 25% 18% 21% 16% 9% 23% 19% 8% 45% 26% 9% 26% 29% 29% Total responders: 2434 971 28 45 97 57 37 334 69 69 33 42 52 108 Footnote: Question wording: What treatments/medications are you currently taking to relieve your itchy skin (choose all that apply)? ; restricted to patients who answered Yes to question Are you bothered at all by itchy skin? (presented in Overall column) and also selected 5 or 6 ( Nearly Always or Always bothered ) on 0 6 scale in response to During the past week, how often have you been bothered by: your itching? ; Rx=prescription, non Rx= non prescription/over the counter, topical = topical (cream or ointment put on skin), oral = oral (medication taken by mouth). Among patients nearly always or always bothered, topical cream use (Rx or non Rx) was 38%, and oral medication use (Rx or non Rx) was 28%. ANZ = Australia and New Zealand, Bel = Belgium, Can = Canada, Chi = China, GCC = the six Gulf Cooperation Council countries (Bahrain, Qatar, Kuwait, Oman, Saudi Arabia, and United Arab Emirates), Ger = Germany, Ita = Italy, Jpn = Japan, Rus = Russia, Spa = Spain, Swe = Sweden, Tur = Turkey, UK = the United Kingdom, US = the United States of America. 10

Supplementary Table 7: Medical Directors drug options for patients with pruritus who are not referred to a specialist. 1: Chronic use, 1st line therapy 2: Chronic use, 2nd line therapy 3: Chronic use, 3rd line therapy 4: Acute use only (i.e., prescribe for 1 month or less) 5: I never prescribe for pruritus N MDs Topical antihistamines 23% 9% 7% 24% 36% 249 Oral antihistamines (over the counter) 32% 13% 3% 21% 31% 238 Oral antihistamines (prescription) 46% 24% 5% 19% 7% 259 IV antihistamines 2% 6% 9% 35% 48% 254 Topical corticosteroids 9% 11% 12% 39% 29% 256 Oral corticosteroids 2% 2% 4% 26% 66% 253 IV corticosteroids 1% 1% 1% 18% 79% 249 Gabapentin 5% 19% 21% 4% 52% 198 Antidepressants 2% 8% 21% 8% 60% 252 Anti anxiolytics/sedatives 2% 6% 20% 19% 53% 251 Opioids 1% 5% 9% 6% 79% 249 Footnote: Question wording: For chronic hemodialysis patients with pruritus whom you do not refer to a specialist, please describe your use of the following drugs options. Medication use categories are not exclusive. Chronic use as 1 st line therapy of prescription or non prescription/over the counter oral antihistamines was 57%. 11

Supplementary Figure 1: Medical Directors estimates of the percentage of patients affected by severe pruritus in their unit, shown by percentage of patients reporting being very much or extremely bothered by itchy skin. Footnote: Facilities were classified by categorizing % patients responding to question: To what extent were you bothered by itchy skin during the past 4 weeks? with very much or extremely at the time of facility recruitment into study (representative study cross section, facilities with <5 patient responses were excluded) and by medical director responses to question Based on your current clinical practice, estimate the percent of patients with severe pruritus. 12

Supplementary Figure 2: Variation between countries in Medical Directors prescribing of gabapentin for pruritus. % Medical directors 100 80 60 40 20 0 N: 21 33 29 59 58 58 57 57 55 67 6 6 90 50 100 33 4 6 8 14 53 21 29 22 35 17 7 22 33 8 29 11 17 21 6 8 14 12 10 4 6 Jpn Rus Spa Can GCC Ita Bel Swe US Tur UK Ger 56 10 18 17 24 12 14 14 49 9 17 14 % patients with gabapentin prescription at any time during DOPPS follow up 0% 0% 2% 12% 8% 2% 2% 4% 21% 13% 9% 7% I never prescribe for pruritus Acute use only, i.e. prescribe for 1 month Chronic use, 3rd line therapy Chronic use, 2nd line therapy Chronic use, 1st line therapy Question text: For chronic hemodialysis patients with pruritus whom you do not refer to a specialist, please describe your use of the following drug options: Gabapentin. ANZ = Australia and New Zealand, Bel = Belgium, Can = Canada, Chi = China, GCC = the six Gulf Cooperation Council countries (Bahrain, Qatar, Kuwait, Oman, Saudi Arabia, and United Arab Emirates), Ger = Germany, Ita = Italy, Jpn = Japan, Rus = Russia, Spa = Spain, Swe = Sweden, Tur = Turkey, UK = the United Kingdom, US = the United States of America. 13